RBC Capital Reiterates Outperform on Neumora Therapeutics, Maintains $29 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated its Outperform rating for Neumora Therapeutics, maintaining a price target of $29.
September 04, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Neumora Therapeutics, maintaining a price target of $29. This suggests confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $29 price target by RBC Capital indicates a positive outlook on Neumora Therapeutics' stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100